IO THERAPEUTICS

Io Therapeutics is discovering and developing a series of retinoid and rexinoid small molecules for the treatment of cancers, neurodegenerative diseases, and autoimmune diseases. The company's lead program is development of IRX4204, a small molecule RXR agonist. The company's focus with IRX4204 is treatment of HER2-positive breast cancer, Parkinson's disease, Alzheimer's disease, normal brain aging, psoriasis, and inflammatory arthritides... Io Therapeutics, Inc. is a privately held biopharmaceutical company headquartered in Houston, Texas. The company's mission is to discover and develop therapeutic compounds targeting nuclear receptors for cancer, neurodegenerative, and autoimmune diseases.

Also known as: Io Therapeutics, Inc.

Primary location: Texas United States